Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €5.98 EUR
Change Today +0.226 / 3.93%
Volume 10.4K
V3V On Other Exchanges
Symbol
Exchange
Xetra
As of 3:15 PM 05/6/15 All times are local (Market data is delayed by at least 15 minutes).

vita 34 ag (V3V) Snapshot

Open
€5.75
Previous Close
€5.75
Day High
€6.05
Day Low
€5.75
52 Week High
04/13/15 - €7.38
52 Week Low
10/13/14 - €3.30
Market Cap
18.1M
Average Volume 10 Days
16.1K
EPS TTM
€0.38
Shares Outstanding
3.0M
EX-Date
07/29/15
P/E TM
15.9x
Dividend
€0.15
Dividend Yield
--
Current Stock Chart for VITA 34 AG (V3V)

Related News

No related news articles were found.

vita 34 ag (V3V) Related Businessweek News

No Related Businessweek News Found

vita 34 ag (V3V) Details

Vita 34 AG operates as an umbilical cord blood bank in Germany, Austria, Switzerland, and Spain. The company operates in two segments, Stem Cell Storage and Biotechnology. The Stem Cell Storage segment collects, processes, and stores stem cells from umbilical cord blood and umbilical cord tissue, as well as develops cell therapy procedures. The Biotechnology segment develops biological processes for cell and tissue culture, as well as employs them in the optimization and multiplication of cells and plants. The company also offers VitaPlusDonation, a program that provides parents an alternative to the pure autologous storage or allogenic donation of umbilical cord blood; and Sibling Initiative program, which allows the free of charge storage of stem cells from the umbilical cord of a child whose brother or sister is seriously ill. It also provides Prevention Screening service, which enables the detection of genetically related health risks and predispositions; and mobile stem cell service that facilitates the treatment with stem cells from umbilical cord blood in various hospitals. The company was founded in 1997 and is headquartered in Leipzig, Germany.

101 Employees
Last Reported Date: 04/23/15
Founded in 1997

vita 34 ag (V3V) Top Compensated Officers

Chief Executive Officer and Member of Managem...
Total Annual Compensation: €264.0K
Chief Financial Officer, Managing Director an...
Total Annual Compensation: €204.0K
Compensation as of Fiscal Year 2013.

vita 34 ag (V3V) Key Developments

VITA 34 AG Reports Earnings Results for the First Quarter of 2015

VITA 34 AG reported earnings results for the first quarter of 2015. For the quarter, the company reported total operating revenue of EUR 3.4 million compared to EUR 3.5 million a year ago. Sales revenue was EUR 3.1 million compared to EUR 3.2 million a year ago. Earnings before interest, taxes, depreciation and amortization (EBITDA) were EUR 0.6 million were at the prior year's level of EUR 0.6 million. Earnings before interest and taxes (EBIT) were EUR 0.3 million were stable at first quarter of 2014 of EUR 0.3 million. In the reporting period 2015 the period result was EUR 0.2 million compared to EUR 0.2 million a year ago. Profit per share was EUR 0.09 in the first quarter of 2015 based on an average number of issued shares of 3,026,500 compared to EUR 0.07 a year ago. This is equivalent to an increase of 28.6% as compared with the prior year.

Vita 34 AG Proposes First Dividend Payment

The earnings per share at Vita 34 AG have increased from EUR 0.28 to EUR 0.36. Because of sustained positive earnings the management board and the supervisory board have resolved to propose to the annual general meeting a first dividend payment in the amount of EUR 0.15 per share.

VITA 34 AG Announces Preliminary Earnings Results for the Full Year of 2014

VITA 34 AG announced preliminary earnings results for the full year of 2014. Total operating revenue increased to EUR 15.2 million in fiscal year 2014 and was 2.7% higher than the prior year's value of EUR 14.8 million. Sales revenues increased to EUR 13.8 million following EUR 13.6 million in fiscal year 2013. The growth in revenues can be mainly attributed to the increased number of newly stored stem cell deposits of umbilical cord blood and tissue. In the reporting period they increased by some 2.9% as compared with the prior year to 7,378 stem cell deposits. EBITDA improved from EUR 2.7 million in fiscal year 2013 to EUR 2.8 million in the reporting period. This is equivalent to a high EBITDA margin of 20.1% (2013: 19.6%). The operating profit (EBIT) increased as well and amounted to EUR 1.7 million in fiscal year 2014, following EUR 1.5 million the prior year, corresponding to an EBIT margin of 12.3% (2013: 10.8%). The period result improved to EUR 1.0 million following EUR 0.8 million in the 2013 reference period. The earnings per share, based on the period result attributable to holders of common stock of the parent company, increased by 28.6% to EUR 0.36 (2013: EUR 0.28).

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
V3V:GR €5.98 EUR +0.226

V3V Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for V3V.
View Industry Companies
 

Industry Analysis

V3V

Industry Average

Valuation V3V Industry Range
Price/Earnings 16.3x
Price/Sales 1.4x
Price/Book 0.8x
Price/Cash Flow 16.3x
TEV/Sales 0.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VITA 34 AG, please visit www.vita34group.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.